SCHEMBL6218644

SCHEMBL6218644

C=CCOC(=O)c1ccc(COCC(N)C#N)o1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.36
RAB9A P51151 5/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
CYP3A4 P08684 1/20 0.36
MAPT P10636 4/20 0.36
HSP90AA1 P07900 3/20 0.36
POLB P06746 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HSD17B10 Q99714 3/20 0.35
TSHR P16473 3/20 0.35
ALDH1A1 P00352 3/20 0.35
HPGD P15428 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 1/20 0.33
TP53 P04637 1/20 0.33
HTT P42858 1/20 0.33
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6218639 1.00 NPC1 (0.36) NPC1RAB9AL3MBTL1CYP3A4MAPT
SCHEMBL6213799 0.77 CYP3A4 (0.39) CYP3A4MAPTHSD17B10TSHRALDH1A1
SCHEMBL6216759 0.76 SLC7A5 (0.41) NPC1RAB9ACYP3A4MAPTSMN1; SMN2
SCHEMBL6216755 0.76 SLC7A5 (0.41) NPC1RAB9ACYP3A4MAPTSMN1; SMN2
SCHEMBL6216743 0.75 CYP3A4 (0.34) CYP3A4MAPTHSD17B10TSHRALDH1A1
SCHEMBL6216697 0.73 CYP3A4 (0.37) L3MBTL1CYP3A4MAPTSMN1; SMN2HSD17B10
SCHEMBL17513682 0.72 CYP3A4 (0.58) CYP3A4MAPTPOLBSMN1; SMN2HSD17B10
SCHEMBL6215267 0.72 CYP3A4 (0.47) NPC1RAB9AL3MBTL1CYP3A4MAPT
SCHEMBL4677464 0.72 CYP3A4 (0.47) NPC1RAB9AL3MBTL1CYP3A4MAPT
SCHEMBL28365597 0.67 CYP3A4 (0.51) NPC1RAB9ACYP3A4MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1283825-B1 N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS NOVARTIS AG (CH) 2005-09-14 EP disclosed
US-6812237-B2 (ARYLAMINOACEAMIDO)ACETONITRILE DERIVATIVES NOVARTIS AG (CH) 2004-11-02 US disclosed
US-20030158256-A1 N-substituted peptidyl nitriles as cysteine cathepsin inhibitors NOVARTIS AG (CH) 2003-08-21 US disclosed
EP-1283825-A1 N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS Novartis AG (CH) 2003-02-19 EP disclosed
WO-2001087828-A1 N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS NOVARTIS AG (CH) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158256-A1 N-substituted peptidyl nitriles as cysteine cathepsin inhibitors CTSS, CTSV, CTSF NPC1 123/4885RAB9A 1299/4885L3MBTL1 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.